Thus, two features of KRAS, the G4 structure in the mRNA and the rare codons in the gene, will prevent the excessive expression of its protein product, and hence its mutations may be favored over mutations in other RAS genes in certain types of cancers. This evidence concerns the gene KRAS and cancer.